Licensing status

Publication and contact



Signal transducer and activator of transcription 5 (STAT5); Janus kinase-2 (JAK-2)

Human tissue and mouse studies suggest inhibiting STAT5 could help treat atopic dermatitis. In patient tissue samples, numbers of mast cells with activated STAT5 were higher in skin lesions than in normal skin. In mouse models of atopic dermatitis, mast cell-specific deletion of Stat5 decreased disease severity compared with Stat5 expression. Also in the models, a JAK-2 inhibitor that blocked Stat5 activation decreased both levels of infiltrating mast cells into skin lesions and disease severity compared with vehicle. Planned work includes additional testing of JAK-2 inhibitors in the models.
Jakafi, a JAK-1 and JAK-2 inhibitor from Incyte Corp. and Novartis AG, is approved to treat myeloproliferative disorder.
At least 10 companies have JAK-2 inhibitors in preclinical or clinical development for multiple indications.

SciBX 7(5); doi:10.1038/scibx.2014.144
Published online Feb. 6, 2014

Unpatented; unlicensed; available for partnering

Ando, T. et al. Cell Rep.; published online Jan. 9, 2014;
Contact: Toshiaki Kawakami, La Jolla Institute for Allergy & Immunology, La Jolla, Calif.